# Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases

> **NCT02707211** · EARLY_PHASE1 · UNKNOWN · sponsor: **Universitaire Ziekenhuizen KU Leuven** · enrollment: 20 (estimated)

## Conditions studied

- Lipid Metabolism, Inborn Errors

## Interventions

- **BIOLOGICAL:** Anti-oxLDL IgM antibody

## Key facts

- **NCT ID:** NCT02707211
- **Lead sponsor:** Universitaire Ziekenhuizen KU Leuven
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707211, "Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02707211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*